Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pitavastatin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR known ✓ | P04035 | 5/20 | 0.85 |
| ▸ | PDE4D | Q08499 | 3/20 | 1.00 |
| ▸ | NR4A2 | P43354 | 2/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 2/20 | 1.00 |
| ▸ | RXRA | P19793 | 3/20 | 0.85 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.54 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.54 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.54 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.54 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.54 |
| ▸ | PGR | P06401 | 1/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.54 |
| ▸ | CCKAR | P32238 | 1/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.54 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.54 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.53 |
| ▸ | ESR1 | P03372 | 1/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.51 |
| ▸ | PDE4A | P27815 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pitavastatin SCHEMBL1582325 | 1.00 | PDE4D (1.00) | PDE4DNR4A2NR1I2HMGCRRXRA | |
| Pitavastatin SCHEMBL6068297 | 1.00 | PDE4D (1.00) | PDE4DNR4A2NR1I2HMGCRRXRA | |
| Pitavastatin SCHEMBL2878734 | 1.00 | PDE4D (1.00) | PDE4DNR4A2NR1I2HMGCRRXRA | |
| Pitavastatin SCHEMBL13278896 | 1.00 | PDE4D (1.00) | PDE4DNR4A2NR1I2HMGCRRXRA | |
| Pitavastatin SCHEMBL6068293 | 1.00 | PDE4D (1.00) | PDE4DNR4A2NR1I2HMGCRRXRA | |
| Pitavastatin SCHEMBL1582328 | 1.00 | PDE4D (1.00) | PDE4DNR4A2NR1I2HMGCRRXRA | |
| Pitavastatin SCHEMBL2878610 | 1.00 | PDE4D (1.00) | PDE4DNR4A2NR1I2HMGCRRXRA | |
| Pitavastatin SCHEMBL13278902 | 1.00 | PDE4D (1.00) | PDE4DNR4A2NR1I2HMGCRRXRA | |
| Pitavastatin SCHEMBL13278898 | 1.00 | PDE4D (1.00) | PDE4DNR4A2NR1I2HMGCRRXRA | |
| Pitavastatin SCHEMBL2878736 | 1.00 | PDE4D (1.00) | PDE4DNR4A2NR1I2HMGCRRXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 28413 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144789-A1 | WOUND TREATMENTS AND COMPOSITIONS | CMPD LICENSING, LLC (US) | 2026-05-28 | — | — | US | claimed |
| US-12636273-B2 | Compositions for pathogenesis-directed therapy and treatments of skin diseases and disorders | YALE UNIVERSITY (US) | 2026-05-26 | — | — | US | claimed |
| US-12640239-B2 | Functional biomarkers for statin therapy in age-related macular degeneration (AMD) | APELIOTUS TECHNOLOGIES, INC. (US) | 2026-05-26 | — | — | US | claimed |
| EP-4745160-A1 | METHOD FOR TREATING OR PREVENTING CHOLESTEROL-RELATED DISEASES USING PCSK9 INHIBITOR | Salubris (Chengdu) Biotech Co., Ltd. (CN) | 2026-05-20 | — | — | EP | claimed |
| US-20260124215-A1 | METHODS OF TREATMENT OF INTESTINAL INFECTIONS | THE FRANCIS CRICK INST LIMITED (GB) | 2026-05-07 | — | — | US | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| WO-2026087680-A1 | TREATMENT FOR CARDIOVASCULAR DISEASE | SAPREME TECHNOLOGIES B.V. (NL) | 2026-04-30 | — | — | WO | claimed |
| EP-4248976-B1 | ANTIGEN BINDING PROTEINS TO PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (PCSK9) | AMGEN INC (US) | 2026-04-22 | — | — | EP | claimed |
| US-12605354-B2 | Azelaic acid esters in the treatment or prevention of dyslipidemia and associated conditions | NEW FRONTIER LABS, LLC (US) | 2026-04-21 | — | — | US | claimed |
| EP-4710928-A2 | METHODS OF TREATING IGA NEPHROPATHY WITH ATRASENTAN | Chinook Therapeutics, Inc. (US) | 2026-03-18 | — | — | EP | claimed |
| US-20020055533-A1 | Pharmaceutical composition | SANKYO COMPANY, LIMITED (JP) | 2002-05-09 | — | — | US | claimed |
| WO-2002032408-A2 | COMBINATIONS OF A THYROMIMETIC COMPOUND AND A STATIN | NOVARTIS AG (CH) | 2002-04-25 | — | — | WO | claimed |
| US-20020032149-A1 | Monitoring blood flow parameter of bloodstream, administering substance to organism such that an amount of substance enters bloodstream; distributing portion of amount ofsubstance target within organism | RHEOLOGICS, INC. | 2002-03-14 | — | — | US | claimed |
| US-20020028826-A1 | HMG-CoA reductase inhibitors and method | BRISTOL-MYERS SQUIBB COMPANY | 2002-03-07 | — | — | US | claimed |
| WO-2002015892-A2 | COMBINATION COMPRISING AN INSULIN SECRETION ENHANCER AND AN ACTIVE INGREDIENT SELECTED FROM HMG-CO-A REDUCTASE INHIBITORS AND ACE INHIBITORS | NOVARTIS AG (CH) | 2002-02-28 | — | — | WO | claimed |
| US-20020013334-A1 | HMG-CoA reductase inhibitors and method | BRISTOL-MYERS SQUIBB COMPANY | 2002-01-31 | — | — | US | claimed |
| WO-2001096347-A1 | HMG-CoA REDUCTASE INHIBITORS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-12-20 | — | — | WO | claimed |
| WO-2001096311-A2 | HMG-COA REDUCTASE INHIBITORS AND THEIR USE AS MEDICAMENTS FOR THE TREATMENT OF CHOLESTEROL RELATED DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-12-20 | — | — | WO | claimed |
| US-20010044584-A1 | In vivo delivery methods and compositions | RHEOLOGICS, INC. | 2001-11-22 | — | — | US | claimed |
| WO-2001076573-A2 | COMBINATION OF AT LEAST TWO COMPOUNDS SELECTED FROM AN AT1-RECEPTOR ANTAGONIST OR AN ACE INHIBITOR OR A HMG-CO-A REDUCTASE INHIBITOR GROUPS | NOVARTIS AG (CH) | 2001-10-18 | — | — | WO | claimed |